Xerthra
Xerthra PRP
Platelet and leukocyte rich plasma
Autologous PRP (platelet rich plasma) concentrate with leukocytes, drawn using a closed system tube with pressure equalization. Indicated for early stage inflammatory wounds and osteoarthritis with active inflammation. The platelets are activated only after administration, modulating the inflammatory process via the leukocytes.
Indications
- Early stage wounds with inflammation
- Advanced stage lesions whose inflammation must be modulated by leukocytes
Xerthra separation system
The Xerthra separation device delivers platelet concentrations up to 12 times higher than unprocessed blood.
- Autologous procedure
- No risk of immune response or disease transmission. Tissues are stimulated by the patient's own growth factors.
- Low blood volume
- Requires only 13.5 ml of blood for the procedure.
- Short centrifugation time
- A fast protocol that preserves sterility and safety.
- Makrolon polymer
- Very low surface energy and low affinity for platelets and leukocytes, ensuring maximum recovery of these factors at the end of the protocol.
- Guaranteed stabilization
- Transverse rings ensure stability during centrifugation, preventing hemolysis.
Technology
Xerthra tube technology
Closed system with pressure equalization
Blood transfer without removing the stopper, eliminating exposure and reducing contamination risk throughout the process.
Very low surface energy
A property of the Makrolon polycarbonate that minimizes platelet and leukocyte adhesion to the tube's inner wall, resulting in greater cell recovery in the final concentrate.
Transverse stabilization rings
Internal structures that keep the blood column stable during centrifugation, preventing hemolysis and preserving the integrity of the separated fractions.
Precision volumetric markings
Allow the exact volume to be obtained at each separation stage, with strict control over the final dose to be applied.
